España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Numinus Wellness
NUMIF
OTCQB
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.0300
0.00014
0.47%
At close: -
$0.0510
0.02
70.00%
After Hours: Nov 15, 9:17 AM EDT
Get Report
Comment
Numinus Wellness (NUMIF) Forecast
News
Earnings
Numinus Wellness (NUMIF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Numinus Wellness (OTC:NUMIF) Stock
Numinus Wellness Stock (OTC: NUMIF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, November 15, 2024
Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions
Juan Spínelli
Friday, September 13, 2024
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Juan Spínelli
Friday, July 12, 2024
Psychedelics Co. Numinus Narrows Loss In Q3, Reports QoQ Decrease In Revenue, Gross Profit
Jelena Martinovic
Saturday, June 22, 2024
Psychedelics-Focused Numinus Plans To Leverage This AI Technology Via New Strategic Acquisition
Jelena Martinovic
Monday, April 15, 2024
Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
Lara Goldstein
Tuesday, March 26, 2024
Two Top Biotechs Forge MDMA Supply Deals For An Expanding Research Field
Lara Goldstein
Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
Lara Goldstein
Saturday, March 16, 2024
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
Lara Goldstein
Thursday, February 15, 2024
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Lara Goldstein
Saturday, January 27, 2024
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
Lara Goldstein
Thursday, January 18, 2024
Numinus Wellness Continues Tight Expense Management With Strategic Reviews Underway
Lara Goldstein
Thursday, January 11, 2024
30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond
Lara Goldstein
Tuesday, December 05, 2023
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Lara Goldstein
Thursday, November 30, 2023
Numinus Reports Q4 & Full Year Fiscal 2023 Results, Including Greatly Reduced Cash Burn Rate
The Dales Report
Friday, September 15, 2023
Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News
Lara Goldstein
Tuesday, September 12, 2023
Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years, NY Consulting Firm Predicts
Lara Goldstein
Tuesday, June 20, 2023
Psyched: $75M In Federal Funds, Gov. Polis Opens MAPS Event, CNN's Show, Dock Ellis' LSD Pitch & More
Lara Goldstein
MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University
Lara Goldstein
Friday, June 16, 2023
Numinus Partners With MAPS To Conduct Phase 1 MDMA Assisted Therapy Investigational Study
The Dales Report
Monday, June 05, 2023
Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study
Lara Goldstein
Wednesday, May 31, 2023
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Lara Goldstein
Tuesday, May 30, 2023
Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
Lara Goldstein
Monday, April 24, 2023
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
Lara Goldstein
Wednesday, April 19, 2023
Numinus Wellness CEO Payton Nyquvest On Q2 2023 Financial Results And Numinus Network
The Dales Report
Monday, April 17, 2023
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Lara Goldstein
Friday, April 14, 2023
Numinus Q2 2023: 581% Revenue Growth, 820% In Gross Profit And Strong Cash Position
Lara Goldstein
Thursday, April 13, 2023
EXCLUSIVE: Infrastructure Built For Healing: 'Consolidation And Legitimacy Are Crucial For Psychedelic Industry Growth'
Joana Scopel
Psychedelic Stock Gainers And Losers From April 13, 2023
Benzinga Insights
Wednesday, April 12, 2023
Psychedelic Stock Gainers And Losers From April 12, 2023
Benzinga Insights
Check Out The Canadian Company Building On Several Vertical Psychedelics Businesses
Lara Goldstein
Numinus Unveils Licensing Model To Independent Practitioners To Expedite Clinic Growth
The Dales Report
Tuesday, April 11, 2023
Psychedelic Stock Gainers And Losers From April 11, 2023
Benzinga Insights
Monday, April 10, 2023
Psychedelic Stock Gainers And Losers From April 10, 2023
Benzinga Insights
Friday, April 07, 2023
Psychedelic Stock Gainers And Losers From April 7, 2023
Benzinga Insights
Thursday, April 06, 2023
Psychedelic Stock Gainers And Losers From April 6, 2023
Benzinga Insights
This Psychiatrist Says Cannabis Is A Minor-League Psychedelic & Undervalued Investment Opportunity
Joana Scopel
Wednesday, April 05, 2023
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
Lara Goldstein
Monday, April 03, 2023
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Benzinga Insights
Monday, March 27, 2023
Want To Become A Psychedelic-Assisted Therapist? This Company Offers A 'Pathway' Course
Lara Goldstein
Wednesday, March 15, 2023
In-Clinic Ketamine Businesses Are Shutting Down All Across The US, A Rising Trend?
Lara Goldstein
Monday, March 13, 2023
EXCLUSIVE: Bienstar Wellness Expands Ibogaine Treatment For Addiction To Curitiba, 3rd Brazilian City Covered By The Co.
Javier Hasse
Thursday, March 09, 2023
Psychedelic Stock Gainers And Losers From March 9, 2023
Benzinga Insights
Wednesday, March 08, 2023
Numinus Wellness, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Benzinga Insights
Will Canada Follow Australia And Approve Psychedelic Assisted Therapy? This CEO Believes It Will
The Dales Report
Monday, March 06, 2023
Psychedelic Stock Gainers And Losers From March 6, 2023
Benzinga Insights
Friday, March 03, 2023
Cybin, GH Research Among Top Psychedelic Movers Of Today
Benzinga Insights
Thursday, March 02, 2023
Psychedelic Stock Gainers And Losers From March 2, 2023
Benzinga Insights
Wednesday, March 01, 2023
Cybin, GH Research Among Top Psychedelic Movers Of Today
Benzinga Insights
Tuesday, February 28, 2023
Psychedelic Stock Gainers And Losers From February 28, 2023
Benzinga Insights
Show More
